The backlash against the high and rising cost of medicines may be cracking the foundation of the convoluted U.S. drug-pricing system, hitting the bottom lines of manufacturers and industry middlemen that have benefited from increases.
from WSJ.com: US Business http://ift.tt/2eNBjDD
via IFTTT
No comments:
Post a Comment